AstraZeneca has announced the availability of Qtern (saxagliptin and dapagliflozin fixed-dose combination) for adult patients with type 2 diabetes in the UK. Marketing authorisation for the tablet was granted by the European Commission on 19 July 2016. It can be taken by adults aged 18 and older with type 2 diabetes in order to improve glycaemic control. The European Commission approval was based on data from three Phase III randomised, double-blind, active/placebo-control, parallel group, multi-centre clinical trials that were carried out on 1,169 adults with type 2 diabetes. Saxa/dapa FDC can be used in patients with mild renal impairment but patients with moderate-to-severe renal impairment, as well as those with end-stage renal disease (ESRD), should avoid taking this tablet. If used alongside a sulphonylurea (SU), the SU dose may need to be reduced in order to minimise the risk of hypoglycaemia.